Topic: colorectal cancer

The data show early signs of efficacy, with one-third of the heavily pretreated lung cancer patients enrolled in the trial having partial responses.

FogPharma has hired Howard Stern, M.D., Ph.D., as its new chief scientific officer and Peter Fekkes, Ph.D., as VP of discovery bioscience.

Exact Sciences is seeing benefits and drawbacks since it kicked off a sales partnership with Pfizer late last year to promote its Cologuard test.

A multi-institution research team has made several surprising discoveries about the role of proteins in colon cancer, which could inspire new treatments.

Positive data from a mouse trial of a cancer-preventing vaccine has Weill Cornell researchers planning a trial in people with a genetic predisposition.

Proteus Digital Health launched a smart chemotherapy pill that aims to help oncologists track effectiveness and adherence in their cancer patients.

CellMax Life was able to detect the small, precancerous colon polyps known as adenomas with close to 90% accuracy using a blood-based test.

Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.

The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.

Boehringer Ingelheim Venture Fund co-led the financing to tee Amal up to take lead colorectal cancer vaccine ATP128 into the clinic next year.